← Eichor
Study identifier: NCT06829381 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Tailored One Anastomosis Gastric Bypass

Condition: Metabolic and Bariatric Surgery  ·  Sponsor: Tel-Aviv Sourasky Medical Center

PhaseNA
Planned participants500
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

One Anastomosis Gastric Bypass (OAGB) is the most common metabolic and bariatric surgery (MBS) in Israel, recognized for its effectiveness in achieving sustainable weight loss and mitigating obesity-related diseases. The metabolic outcomes of OAGB are significantly influenced by the length of the biliopancreatic limb (BPL). The objective of this study is to determine whether tailoring the BPL length to the total small bowel length (TSBL) results in more effective weight loss compared to patients undergoing OAGB with a fixed BPL of 180 cm. Efficacy and safety of this approach will also be evaluated, ensuring it does not lead to long-term morbidity or negatively impact patients' quality of life.

This description comes directly from the study's public registry record.

Talk to the study team

Adam Abu-Abeid, M.D  ·  +972524266283  ·  adama@tlvmc.gov.il

Always discuss trial participation with your own doctor first.

Locations (1)

Tel Aviv Sourasky Medical CenterTel Aviv, IsraelRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06829381